Fig. 3.

Comparison of anti-CD16 clones on observed neutrophil PD-L1 expression in healthy young, healthy elderly and COPD participants.

Neutrophils from (A) n = 6 healthy young (HY), (B) n = 4 healthy elderly (HE) and (C) n = 6 COPD participants were stained with anti-PD-L1 (BioLegend, Clone 29E.2A3) and co-stained with (+) or without (−) four different anti-CD16 antibodies: either different clones (i-ii, 3G8; iii, eBio-CB16; iv, VEP-13) or different manufacturers (i, Biolegend; ii, Invitrogen; iii, eBiosciences; iv, Miltenyi). Samples were analysed by flow cytometry, data expressed as median fluorescence intensity (MFI) per donor compared to single stained PD-L1 neutrophils. P-values determined using Wilcoxon matched-pairs signed rank test.